Trial Profile
Placebo controlled study of rosiglitazone in HIV lipoatrophy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Atherosclerosis; Hyperlipidaemia
- Focus Biomarker; Pharmacodynamics
- 02 Mar 2010 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 May 2008 The expected completion date for this trial is now 1 Apr 2009 (source: ClinicalTrials.gov).